Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
50 results about "Deferoxamine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
This medication is used along with other treatments (such as causing vomiting with syrup of ipecac, stomach pumping) to treat sudden iron poisoning.
Compositions and methods of delivery of pharmacological agents
InactiveUS20050004002A1Reducing one or more side effectsInhibiting oxidation in the pharmaceutical compositionAntibacterial agentsOrganic active ingredientsSide effectPharmaceutical formulation
The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and / or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
Owner:ABRAXIS BIOSCI LLC
Compositions and methods of delivery of pharmacological agents
InactiveUS20070129448A1Eliminate side effectsInhibit microbial growthBiocideHydroxy compound active ingredientsSide effectPharmaceutical formulation
The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serun albumin and / or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharrmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
Owner:ABRAXIS BIOSCI LLC
Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning
ActiveUS20060039995A1Minimize impactAvoid unwantedHeavy metal active ingredientsBiocideAntioxidantNose
Methods and pharmaceutical compositions for preconditioning and / or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and / or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and / or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and / or post stroke.
Owner:HEALTHPARTNERS RESEACH FOUND
Methods and pharmaceutical compositions for differentially altering gene expression to provide neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma and metal poisoning
ActiveUS20070092500A1Preventing and minimizing and treating neurologic complicationAvoid side effectsOrganic active ingredientsBiocideAntioxidantNose
Methods and pharmaceutical compositions for preconditioning and / or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and / or stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. In another embodiment, the method is accomplished by differentially reducing, inhibiting or preventing the increased expression of selected genes caused by neurological disorders. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease, Huntington's disease, thalassemia or stroke, or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and / or copper such as iron chelators, copper chelators, and antioxidants. Particular examples of such therapeutic agents are the iron chelators deferoxamine (DFO) and deferasirox. Intranasal administration of DFO is known to stimulate and / or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia.
Owner:HEALTHPARTNERS RESEACH FOUND
Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
ActiveUS7618615B2Minimize impactAvoid side effectsBiocideHeavy metal active ingredientsNasal cavityNervous system
Methods and pharmaceutical compositions for preconditioning and / or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and / or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and / or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and / or post stroke.
Owner:HEALTHPARTNERS RESEACH FOUND
Combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
Synergistic compositions and methods are disclosed for using cruciferous indoles with iron / zinc chelators in the treatment of papillomavirus-related conditions. These synergistic compositions of diindolylymethane (DIM), related trimeric derivatives, and related indole derivatives include combinations with deferoxamine, deferiprone, bipyridyl, Desferri-exochelin, picolinic acid, 3-hydroxypicolinic acid, and sodium butyrate as iron / zinc chelators. The methods described comprise more effective therapies for common cutaneous warts (verrucae) and related dysplasias of the oropharynx, genitalia, and uterine cervix.
Owner:BIORESPONSE
Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning
ActiveUS20100061959A1Minimize impactAvoid side effectsBiocideHeavy metal active ingredientsNasal cavityNervous system
Owner:HEALTHPARTNERS RESEACH FOUND
Artificial medicine carrying coaxial regenerated intravascular stent and compound process preparation method thereof
ActiveCN107898533ABiocompatiblePromote generationStentsPharmaceutical delivery mechanismCross-linkBlood vessel
The invention discloses an artificial medicine carrying coaxial regenerated intravascular stent and a compound process preparation method thereof. The intravascular stent is provided with a three-layer structure which is prepared through different process methods, an inner-layer material adopts a deferoxamine DFO+PVA core layer solution and a PCL shell layer solution, and a coaxial electrospinning forming process is adopted; a middle-layer material adopts a PVA+SA mixed solution, a dipping method forming process is adopted, and calcium chloride is adopted for cross linking after outer layer electrospinning is carried out; an outer-layer material adopts a gentamicin GS+PVA core layer solution and a PCL shell layer solution, and the coaxial electrospinning forming process is adopted. The three-layer medicine carrying intravascular stent is prepared through the two processes by compounding different materials, the three-layer structure of a natural blood vessel is simulated well, the time needed by in-vitro culture and transplantation is shortened, the success rate is increased, and the intravascular stent has wide prospects in clinical application.
Owner:SHANGHAI UNIV
Bone repair material and preparation method thereof
ActiveCN111888521AAvoid the risk of further fracturesPromote ingrowthAntibacterial agentsPharmaceutical delivery mechanismBiocompatibilityCell growth
The invention discloses a bone repair material as well as a preparation method and application thereof. The bone repair material comprises the following components: magnesium oxide, monocalcium phosphate, sodium dihydrogen phosphate and calcium-deficient hydroxyapatite. The molar ratio of the magnesium oxide to the monocalcium phosphate to a sodium dihydrogen phosphate bone cement powder is 6:1:4,5:1:3 or 3:1:1, and the calcium-deficient hydroxyapatite accounts for 20% of the total mass. A curing liquid of the bone cement is an EGCG aqueous solution, and the concentration is 120 [mu]mol / L. Aloaded drug is deferoxamine. The preparation method of the bone repair material is simple and feasible; and the setting time is suitable, the bone cement has good biocompatibility, osteogenesis and degradability, and can promote adhesion, proliferation and differentiation of osteoblasts, stimulate cell growth and stimulate differentiation of the osteoblasts into the osteoblasts, and the bone repair material can be directly injected into a bone defect part.
Owner:上海禾麦医学科技有限公司
Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
ActiveUS7776312B2Avoid side effectsStimulate and stabilize HIF-1αBiocideOrganic active ingredientsNervous systemNose
Owner:HEALTHPARTNERS RESEACH FOUND
Method for dissociating iron coordination polymer nanoparticles and application thereof
ActiveCN107670036AFast dissociationQuick clearEnergy modified materialsEchographic/ultrasound-imaging preparationsEthylenediamineAcetic acid
The invention provides a method for dissociating iron coordination polymer nanoparticles. The method comprises the steps that the iron coordination polymer nanoparticles are dissociated by a dissociation agent which is one or more selected from a group consisting of deferoxamine, deferiprone, ethylenediamine tetraacetic acid and ethylenediamine tetraacetic acid disodium salt. The iron coordinationpolymer nanoparticles are prepared from polyphenol, trivalent iron salt and macromoleclar polymer. The special dissociation agent is adopted to dissociate the iron coordination polymer nanoparticles.Under the action of the dissociation agent, the iron coordination polymer nanoparticles can be quickly dissociated into small nanoparticles or a small molecular solution. The dissociating method canquickly remove the iron coordination polymer nanoparticles in vivo and particularly the iron coordination polymer nanoparticles at the position of the liver, and reduce potential damage to the liver.
Owner:CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI
Desferrioxamine-metal complexes for the treatment of immune-related disorders
ActiveUS20120220651A1Achieve therapeutic effectAmeliorate physiological manifestationBiocideSenses disorderDiabetes mellitusAutoimmune condition
The present invention relates to methods kits and combined compositions using DFO-metal complexes, specifically, Zinc-desferrioxamine (Zn-DFO), gallium-desferrioxamine (Ga-DFO) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune disease such as diabetes and any immune-related disorder.
Owner:CHEVION MORDECHAI
Preparation method of multifunctional electrospinning scaffold for bone regeneration
ActiveCN113842504AEfficient removalRegenerationBone implantConjugated cellulose/protein artificial filamentsLysophosphatidic acidPhosphatidic acid
The invention provides a preparation method of a multifunctional electrospinning scaffold for bone regeneration. The method belongs to the field of tissue engineering and regenerative medicine, and comprises the following specific steps: 1, preparing lysophosphatidic acid nanoparticles and deferoxamine nanoparticles; 2, preparing a medical polymer mixed solution and dividing the medical polymer mixed solution into two equal parts; 3, preparing a coaxial electrospinning shell layer solution from the lysophosphatidic acid nanoparticles, zinc oxide nanoparticles and the medical polymer mixed solution; 4, preparing a coaxial electrospinning core layer solution from the deferoxamine nanoparticles and another medical polymer mixed solution; 5, preparing the electrospinning scaffold with a core-shell structure; and 6, performing vacuum drying until a solvent is removed, thereby finally obtaining the product. According to the prepared multifunctional electrospinning scaffold for bone regeneration, the lysophosphatidic acid nanoparticles and the zinc oxide nanoparticles are arranged on the shell layer, the deferoxamine nanoparticles are arranged on the core layer, and the electrospinning scaffold has the functions of resisting bacteria, promoting osteogenesis, promoting revascularization and the like at the same time and can be used for repairing bone tissues in a complex microenvironment.
Owner:THE SECOND HOSPITAL AFFILIATED TO SUZHOU UNIV
Polylactic-acid-based bone tissue support loading icariin and deferoxamine and preparation method and application of polylactic-acid-based bone tissue support
ActiveCN108096630AGood mechanical propertiesPromote formationElectro-spinningTissue regenerationFiberSeparation technology
The invention belongs to the field of a biomedical material, and specifically relates to a polylactic-acid-based bone tissue support loading icariin and deferoxamine, and a preparation and applicationof the polylactic-acid-based bone tissue support. Electrospinning technique is adopted to prepare a polylactic acid micrometer fiber support, which is then modified with a polydopamine layer, and finally, polydopamine is used for synergetic fixing of icariin and deferoxamine to the support. Through utilization of polydopamine, the hydrophilic performance, mechanical properties and cell affinity of the support are improved, and through cooperation of icariin and deferoxamine, the ossification performance and hematopoietic performance of the support are greatly improved. Through further adoption of thermally-induced phase separation, a chitosan nanometer fiber net is compounded on the polylactic acid micrometer fiber support, and based on the composite nanometer fiber net, polydopamine, icariin and deferoxamine are used for modification. The mechanical property of the support is obviously improved, which is beneficial for forming vasoganglion. The used materials are cheap, the adopted electrospinning and thermally induced phase separation technology are simple, and the performance of the material is easy to regulate, so that the support is suitable for industrialization.
Owner:广州倍健医疗用品有限公司 +1
Nanometer particles with iron chelators encapsulated in amphiphilic polymers and preparation method and application thereof
ActiveCN104856960AValid entryGood curative effectPowder deliveryMetabolism disorderSide effectIron Chelator
The invention provides a kind of nanometer particles with iron chelators encapsulated in amphiphilic polymers and a preparation method and application thereof. The nanometer particles are formed in the mode that water-soluble chelators are encapsulated in amphiphilic polymers. According to the method, the amphiphilic polymers serve as carriers, and the nanometer particles with iron chelators encapsulated in amphiphilic polymers are obtained through a multiple emulsion method. The obtained nanometer particles are stable, the half-life period of the iron chelators in blood circulation in vivo is prolonged, the iron chelators are transported to target organs in a targeting manner, nanometer drugs containing the nanometer particles with iron chelators encapsulated in amphiphilic polymers can be used for treating iron-overloaded diseases, the iron chelators release slowly so that deferoxamine can metabolize in a human body, more iron chelators can enrich in viscera, the curative effect of the drugs is improved, the toxic and side effect on cells is reduced, and the iron chelators can remove iron in cells more efficiently.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA
Application of deferoxamine to preparation of medicine for treating nonalcoholic fatty liver
ActiveCN107184570AImprove securitySmall side effectsDigestive systemAmide active ingredientsLiver tissueSolvent
The invention discloses a novel usage of deferoxamine, namely application of the deferoxamine to preparation of a medicine for treating nonalcoholic fatty liver. The application of a substance A or a substance B or a substance C to the preparation of the medicine is protected for the first time; the substance A is the deferoxamine; the substance B is pharmaceutically acceptable salt of the deferoxamine; the substance C is a solvate of the deferoxamine; the medicine is used for treating and / or preventing fatty liver. The inventor proves that the deferoxamine can be used for remarkably relieving liver tissue pathological changes induced by high cholesterol through establishing a high-cholesterol animal model, alleviating injuries to liver cells and reducing intrahepatic lipid accumulation. The novel usage of the deferoxamine is developed, and a new way is provided for treating the nonalcoholic fatty liver.
Owner:INST OF GENETICS & DEVELOPMENTAL BIOLOGY CHINESE ACAD OF SCI
Methods of extending mammalian life span via iron chelating compounds that reduce free radical damage in mammals
InactiveUS20050020672A1Extend your lifeReducing free radical damageBiocideKetone active ingredientsFurildioximeIron Chelating
The subject invention involves a method of extending the life span of mammals by reducing free radical damage in mammals wherein the method comprises administering to a mammal a composition comprising a safe and effective amount of a compound selected from 1-phenyl-1,2-propanedione-2-oxime, benzoylacetone, piroctone, 2-furildioxime, 2-furilmonoxime, diethyldithiocarbamic acid, deferoxamine and 1,2-dimethyl-3-hydroxy-pyrid-4-one, or a pharmaceutically acceptable salt thereof, or mixtures of the subject compounds and / or their salts.
Owner:THE PROCTER & GAMBLE COMPANY
Methods of treating huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
ActiveUS20140179789A1Preventing and minimizing and treating neurologic complicationReduce weight lossBiocidePeptide/protein ingredientsHuntingtons choreaNasal cavity
Methods for preconditioning and / or providing neuroprotection to the animal central nervous system against the effects of Huntington's disease. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and / or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with Huntington's disease. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and / or treating Huntingon's disease.
Owner:HEALTHPARTNERS RESEACH FOUND
Polyethylene glycol modified iron ionic chelator
ActiveCN107281498AExtended half-lifeLow toxicityNervous disorderPharmaceutical non-active ingredientsPolyethylene glycolBiocompatibility Testing
The invention discloses a polyethylene glycol modified iron ionic chelator and a preparation method thereof. The iron ionic chelator is prepared from derivatives of polyethylene glycol with good biocompatibility and deferoxamine. The preparation method comprises the step of preparing the polyethylene glycol modified iron ionic chelator by covalent binding of carboxylated polyethylene glycol monomethyl ether or formylated polyethylene glycol monomethyl ether with deferoxamine. Compared with deferoxamine, the iron ionic chelator has the advantages of long action and low toxicity, and has potential application value in treatment of iron overload related diseases.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Application of deferoxamine to preparation of medicine for preventing and/or treating tumor
ActiveCN109316474AGood treatment effectIncrease lethalityAmide active ingredientsAntineoplastic agentsTherapeutic effectOncology
The invention provides application of deferoxamine to preparation of medicine for preventing and / or treating tumor, and relates to the technical field of tumor science. According to the application ofdeferoxamine to the preparation of medicine for preventing and / or treating the tumor, the dose form of the medicine is an injection or a tablet; the tumor is glioma or human lung carcinoma cells. Inthe medicine, 125 to 500 mumol / L of deferoxamine and 100 mumol / L of temozolomide are contained. Through experiment methods, the result proves that the treatment effect of the temozolomide on the glioma or human lung carcinoma cells can be enhanced; the effect of cooperating with temozolomide to killing glioma or human lung carcinoma cells is achieved; the killing effect of the temozolomide on theglioma or human lung carcinoma cells can be enhanced. The deferoxamine and the temozolomide are prepared into medicine used for preventing and / or treating the glioma or human lung carcinoma cells; thetreatment effect of the temozolomide on the brain glioma or human lung carcinoma can be improved.
Owner:葛鹏飞
NK cell in-vitro proliferation method and culture medium
PendingCN113684178ACulture processBlood/immune system cellsNatural Killer Cell Inhibitory ReceptorsCell immunity
The invention relates to the field of cellular immunotherapy, in particular to an NK cell in-vitro proliferation method and a culture medium suitable for the method, and particularly relates to a cell culture medium taking deferoxamine as an effective component.
Owner:惠州腾大健康科技有限公司
Long circulation iron chelator with pH response characteristic
ActiveCN107141468AExtended half-lifeLow toxicityOrganic active ingredientsMetabolism disorderDiseaseIron Chelator
The invention discloses a long circulation iron chelator with a pH response characteristic. The long circulation iron chelator is formed by connecting polyethylene glycol monomethyl ether with good biocompatibility and deferoxamine through a pH sensitive chemical bond. The invention further discloses a preparation method of the long circulation iron chelator, and the preparation method comprises the steps of connecting polyethylene glycol monomethyl ether with carboxybenzaldehyde through an esterification reaction, and enabling an intermediate product to react with the deferoxamine through a schiff base to prepare the long circulation iron chelator with the pH response characteristic. Compared with the deferoxamine, the disclosed iron chelator has the characteristics of long effect and response to an acid micro-environment of a lesion location, and has a potential application value in the treatment of iron overload related diseases.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Injectable antioxidant formulation for intravenous use of sodium ascorbate in high dosage, n-acetyl cysteine, and deferoxamine; method of administration and use for preventing injury due to reperfusion; and kit
InactiveUS20170333393A1Avoid injuryPromote resultsPharmaceutical containersPharmaceutical delivery mechanismReperfusion injurySodium ascorbate
The invention refers to an injectable antioxidant formulation for intravenous use comprising sodium ascorbate in high dosage as a first antioxidant agent, N-acetyl cysteine as a second oxidant agent and deferoxamine as an iron chelating agent, plus pharmaceutically acceptable excipients. And an administration method of said formulation that results in a synergic and improved effect to prevent injury due to reperfusion in an organ. In particular, to prevent injury due to early and late reperfusion in patients diagnosed with acute myocardium infarction and indication of primary coronary angioplasty. The invention further refers to the use of the formulation to prevent injury due to reperfusion in patients with acute myocardium infarction, subjected to primary coronary angioplasty.
Owner:UNIVERSITY OF CHILE
Methanesulfonic acid deferoxamine adjuvant and vaccine comprising methanesulfonic acid deferoxamine adjuvant
ActiveCN103736090ASmall side effectsRaw materials are easy to getImmunological disordersAntibody medical ingredientsResponse effectSide effect
The invention provides a methanesulfonic acid deferoxamine adjuvant and a vaccine comprising the methanesulfonic acid deferoxamine adjuvant. A single part of the vaccine comprising the methanesulfonic acid deferoxamine adjuvant comprises 0.6-8mg methanesulfonic acid deferoxamine adjuvant. The methanesulfonic acid deferoxamine adjuvant is applied to clinical treatment for a long term, has small toxic and side effects, is safe and reliable to use within an immunizing dose scope, and can effectively induce antigen-specific humoral immunity response, the induced humoral immunity response effect is better than that of a group without the adjuvant, a raw material of the methanesulfonic acid deferoxamine adjuvant is easy to obtain and is a marketed product, and the methanesulfonic acid deferoxamine adjuvant is simple in preparation technology, low in cost and stable in performance, and can be added to various traditional vaccines and genetic engineering vaccines as a vaccine adjuvant.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Deferoxamine derivative compound with bone affinity, preparation method and application thereof
The invention develops a deferoxamine derivative with bone affinity, a preparation method and application thereof. More specifically, the invention provides a compound with a structure shown as formula (1) and its pharmaceutically acceptable salt, ester, amide, acyl halide, hydrate or solvate. The invention also provides a preparation method of the compound shown as formula (1) and application thereof in preparation of drugs for treatment of osteoporosis, osteonecrosis, delayed union or nonunion and bone defect. (formula I).
Owner:上海市伤骨科研究所
Desferrioxamine conjugates, derivatives and analogues
InactiveUS8309583B2More resistant to in vivo enzymatic degradationExtended half-lifeBiocideNervous disorderMalariaDeferoxamine
The present invention relates to desferoxamine conjugates, derivatives and analogues thereof. In particular, the present invention relates to desferoxamine conjugates, analogues and derivatives thereof, and methods for reducing levels of metals, especially iron, in a mammal. Uses of the compounds according to the invention are also provided. Compounds of the present invention may also be used to treat iron dyshomeostasis disorders, cancer, malaria and fungal infections. The compounds of the invention may be formulated into a pharmaceutical composition or packaged into kits.
Owner:THE UNIV OF SYDNEY
Synthesis method of ferrioxamine succinimide activated ester and application thereof
PendingCN111410625AEasy to manufactureLow costOrganic chemistryRadioactive preparation carriersSaflufenacilRadioactive drug
The invention belongs to the technical field of radiopharmaceutical labeling, and particularly relates to a synthesis method of ferrioxamine succinimide activated ester and an application of saflufenacil succinimide activated ester in preparation of radiopharmaceutical. According to the invention, deferoxamine (DFO) is used as a raw material to synthesize the ferrioxamine succinimide activated ester. The activated ester can be subjected to an amide condensation reaction with drug molecules with primary amino groups under a mild condition to generate an iron oxadiazon conjugate, and then ferricions are removed by a metal chelating agent through a competitive reaction to obtain a deferoxamine conjugate. The invention also relates to the use of the radiolabeled deferoxamine conjugate as an imaging agent and a therapeutic agent, by using medical radionuclides (such as 89Zr, 68Ga, 67Ga, 177Lu, 111In, 90Y) to efficiently label the deferoxamine conjugate, the generated labeled drug can be used for living PET imaging, SPECT imaging or radiotherapy.
Owner:NANJING PET TRACER
Amine pegylation methods for the preparation of site-specific protein conjugates
InactiveCN107708679ALow immunogenicityProlonged Circulatory Half-LifeOrganic active ingredientsPeptide/protein ingredientsProtein solutionFER protein
Examples include a method of making a protein-PEG conjugate. The method may include providing an aqueous protein solution. The aqueous protein solution may include a protein, a pH buffer, and a chelating agent. The chelating agent may be chosen from the group consisting of an aminopolycarboxylic acid, a hydroxyaminocarboxylic acid, an N-substituted glycine, 2-(2-amino-2-oxocthyl) aminoethane sulfonic acid (BES), and deferoxamine (DEF). The method may also include introducing sodium cyanoborohydride and a methoxy polyethylene glycol aldehyde to the aqueous protein solution. The sodium cyanoborohydride in the methoxy polyethylene glycol aldehyde may have a molar ratio ranging from about 5:1 to about 1.5:1. The method may further include reacting the methoxy polyethylene glycol aldehyde withthe protein to form the protein-PEG conjugate. The pH buffer may maintain a pH of the aqueous protein solution ranging from 4.0 to 4.4 during the reaction.
Owner:REZOLUTE INC
Acute and chronic mitochondrial electron transport chain dysfunction treatments and graphenic materials for use thereof
InactiveUS20200222453A1Facilitates intracellular transportMinimize consequencesPowder deliveryHeavy metal active ingredientsMitochondrial electron transportBinding site
Modified hydrophilic carbon clusters (HCCs), poly(ethylene glycol)-hydrophilic carbon clusters (PEG-HCCs) and similarly structured materials like graphene quantum dots (GQDs), PEGylated GQDs, small molecule antioxidants, and PEGylated small molecule antioxidants. These materials have been modified with an iron chelating moiety, deferoxamine, or a similar chelating moiety. By exploiting common binding sites, the carbon nanostructure facilitates intracellular transport including in mitochondria, reduces oxidative breakdown of the chelator moiety prior to treatment, and reduces both the cause and consequences of metal induced oxidative stress within the body thus providing a novel form of therapy for a range of oxidative and metal-related toxicities. Graphenic materials can be used for the treatment of acute and chronic mitochondrial electron transport chain dysfunction.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +3
Stem cell scaffold applied to iron overload region, and preparation method thereof
ActiveCN109010914APromote growthImprove survival rateTissue regenerationProsthesisHigh cellCerebral hemorrhages
The invention discloses a stem cell scaffold applied to an iron overload region. The stem cell scaffold is a double-layered keratin gel cell having a concentric structure; the stem cell scaffold is composed a low-molecular weight keratin hydrogel outer layer coated with deferoxamine and a high-molecular weight keratin hydrogel inner layer wrapped with stem cells and trophic factors; and the stem cell scaffold is the double-layer concentric structure, the inner layer provides cell growth, and the outer layer eliminates the unfavorable environment, so cell growth is improved, the survival rate is increased, and the stem cell scaffold achieves a higher cell survival rate and a better effect than traditional transplanted cells after cerebral hemorrhage. The double-layered keratin gel cell scaffold is injected into the cerebral hemorrhage site in order to rapidly adsorb residual overload iron ions surrounding hematoma tissues by the adsorption effect of gel and release embedded drugs for chelating the iron ions, so the iron overload is eliminated; and the transplanted stem cells provide a neuroprotection effect, and can be differentiated into neurons and glial cells to repair damaged parts.
Owner:海默斯(重庆)医学生物技术有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com